Slide 1: Three Platforms, One Mission: Transforming Advanced Cancer Care
Three Platforms, One Mission: Transforming Advanced Cancer Care NASDAQ: RNAZ
Slide 2: Company Forward Looking Statement
Company Forward Looking Statement 2 Before you invest in the securities of TransCode Therapeutics, Inc. (“TransCode” or the “Company”), you should read TransCode’s filings with the U.S. Securities and Exchange Commission (“SEC”) for more complete information about the Company. You can obtain these d
Slide 3: A Rare Small-Cap with Three Near Term Catalysts
A Rare Small-Cap with Three Near Term Catalysts 3 Harvard-faculty founders Massachusetts General Hospital (MGH) /Harvard Medical School (HMS) to target advanced cancers Since the Company’s initial public offering in 2021, ~$100 million net invested to date through financings and grants; no long-term
Slide 4: Critical Need for Effective Therapies Targeting Advanced Cancer
Critical Need for Effective Therapies Targeting Advanced Cancer 4 Cancer Deaths Due to Advanced Disease >90% Advanced Cancer Reduces 5-year Survival Key Challenge to Treatment Dissemination to distant sites, immune evasion, resistance Global Market by 2032* $120-$250B *Source: 2019 American Cancer S
Slide 5: Experienced Management
Experienced Management Tom Fitzgerald, MBA CFO; Director Zdravka Medarova, PhD Cofounder, CSO Susan Duggan, RN, MBA SVP Operations Tania Montgomery VP Business Development Philippe P Calais, PharmD PhD CEO, Chairman of the Board Michel Janicot, PhD Consulting Head Translational Science Daniel Vlock,
Slide 6: Leading Advisors with Oncology and RNA Expertise
Leading Advisors with Oncology and RNA Expertise 6 Keith Flaherty, MD Professor of Medicine & Director of Clinical Research Mass General Cancer Center Lubo Nechev, PhD Chief CMC Officer, Alnylam Pharmaceuticals Dejan Juric, MD Director, Termeer Center for Targeted Therapies Massachusetts General Hos
Slide 7: Innovative and Differentiated Pipeline
Innovative and Differentiated Pipeline 7
Slide 8: TTX-MC138 Lead Therapeutic Candidate
8 TTX-MC138 Lead Therapeutic Candidate AntagomiR targeting microRNA-10b Phase 2a active
Slide 9: TTX-MC138 Mechanism of Action
TTX-MC138 9 TWIST1 TTX-MC138 miR-10b NF1 ROCK cJUN HOXD10 E-Cadherin TBX5 PTEN AKT Select miR-10b Molecular Pathways RHOC Key Components of Tumor Invasion and Metastases Immune evasion Tumor cell motility & metastasis Anti-apoptosis & cell proliferation Improved self-renewal: Proliferation, apoptosi
Slide 10: Clinical Development Plan: Metastatic Disease
Clinical Development Plan: Metastatic Disease 10 Phase 1a Dose escalation, all comers, advanced solid tumors Phase 0 Microdose radiolabelled, advanced solid tumors Phase 2a Dose expansion Micrometastatic disease Phase 2 First indication TBD Phase 0 Phase 1a Phase 2a Phase 2 Indications: Advanced sol
Slide 11: Phase 0: Accumulation in Metastatic Lesions Confirmed
Phase 0: Accumulation in Metastatic Lesions Confirmed 11 • Dosed 1 female patient with stage-IV metastatic breast cancer (metastatic sites: bone, liver and lungs – left panel) • Single sub-therapeutic dose of labelled TTX-MC138 • PET-MRI performed at 2, 3, 6 and 24 hours post-dosing (right panel) •
Slide 12: Phase 1a Trial: Overview and Status
Phase 1a Trial: Overview and Status 12 Dose escalation, 4 cohorts of 3 + patients Advanced solid tumors, all comers Objectives Endpoints Primary Objectives Primary Endpoint Evaluate safety and tolerability, determine MTD and select RP2D Incidence of TEAEs* Secondary Objectives Secondary Endpoints Ev
Slide 13: Phase 1a Trial: Subject Tumor Type
13 Phase 1a Trial: Subject Tumor Type Subject # Dose Level Type of cancer diagnosed Location 100-003 0.8 mg/kg Malignant neoplasm of endometrium Uterus 103-001 0.8 mg/kg Solitary fibrous tumor (hemangiopericytoma) Right forehead 100-002 0.8 mg/kg Adenocarcinoma of the rectum Rectum 100-004 1.6 mg/kg
Slide 14: Phase 1a Trial: Safety
14 Phase 1a Trial: Safety Primary Endpoint Cohort Dose Number of Patients DLT’s 1 0.8mg/kg 3 0 2 1.6mg/kg 3 0 3 3.2mg/kg 6 0 4 4.8mg/kg 3 0 Treatment Related Serious Adverse Events (SAE) SAE # Subjects (N=16) % Subjects Grade Infusion Related Reaction* 1 6.25% 2 * SAE due to hospitalization observat
Slide 15: Phase 1a Trial: Safety Overview
15 Phase 1a Trial: Safety Overview Adverse Events Adverse Event (Maximum CTCAE Grade) Total (N=16) Nausea 2 (12.5%) Grade 1 2 (12.5%) Hyponatremia 3 (18.8%) Grade 2 1 (6.3%) Grade 1 2 (12.5%) Iron overload 2 (12.5%) Grade 1 1 (6.3%) Grade 3* 1 (6.3%) Back pain 3 (18.8%) Grade 1 3 (18.8%) Dyspnea 3 (
Slide 16: Phase 1a Trial: Pharmacokinetic Results
16 Phase 1a Trial: Pharmacokinetic Results Pharmacokinetic profile from the analysis of plasma from patients receiving TTX-MC138 demonstrated evidence of drug availability consistent with preclinical data Mean concentrations on C1D1 Supra-proportional Dose and AUC 16
Slide 17: Phase 1a Trial: Efficacy Analysis
17 Phase 1a Trial: Efficacy Analysis Best Overall Response Evaluable Subjects (N=14) Complete Response 0 (0%) Partial Response 0 (0%) Stable Disease 9 (64.3%) Progressive Disease 3 (21.4%) Not Evaluable 2 (14.3%) Overall Response Rate Swimmers Plot Response Categories Durable disease stabilization i
Slide 18: Phase 1a Trial: Thyroid Cancer Case
18 Phase 1a Trial: Thyroid Cancer Case Patient 103-003 with metastatic thyroid cancer with lung metastases Thyroglobulin levels • Associated with increased tumor burden • Dropped to 0 after 6 cycles • Stable disease radiographically C7 and C8 Dose held • Possibly related to elevated TSAT/Ferritin le
Slide 19: Phase 2a Trial: TTX-MC138 in Colorectal Cancer
19 Phase 2a Trial: TTX-MC138 in Colorectal Cancer Targeting minimal residual disease Opportunity: Address unmet medical need by evaluating TTX-MC138 in colorectal patients post adjuvant treatment with curative intent Mechanism of Action: Evaluate TTX-MC138 in micrometastatic setting where no options
Slide 20: Phase 2a Study: Quantum Leap Healthcare Collaboration
20 Phase 2a Study: Quantum Leap Healthcare Collaboration Accelerate Success - Partnership with the Quantum Leap Healthcare Collaborative oncology platform study Rapid Study Initiation - Ready-to-deploy infrastructure and parallel regulatory approvals enable swift clinical study activation Leverage E
Slide 21: Phase 2a Trial Design: Single Arm Open Label
21 Phase 2a Trial Design: Single Arm Open Label Patient Selection ctDNA+ after curative-intent standard therapy ctDNA Monitoring Serial ctDNA analysis every cycle (primary endpoint assessment) Response Assessment ctDNA clearance →MRD Negativity, MRD Conversion, Depth of MRD Response Readout May supp
Slide 22: Seviprotimut-L Cancer Vaccine
22 Seviprotimut-L Cancer Vaccine
Slide 23: Seviprotimut-L: Overview and Unmet Needs
Seviprotimut-L: Overview and Unmet Needs 23 • FDA “Orphan Drug” status • Successful completion of adaptive Phase 3 clinical trial “MAVIS” • FDA “Fast Track” designation • Peer reviewed publication (JITC) • Planned Phase 3 (“MELISSA”) potential for confirmatory trial ⎼ FDA Special Protocol Assessment
Slide 24: Seviprotimut-L: MAVIS Clinical Trial Design & Efficacy Results
Seviprotimut-L: Phase 3 MAVIS Clinical Trial Design & Efficacy Results 24 Study Drug • 40 µg seviprotimut* vs placebo Study Population • Ages 18 to 80, female and male • Stage IIB/IIC, IIIA, and IIIB/IIIC melanoma patients, resected with clear margins • Resection within 90 days of first dose • No ot
Slide 25: Pre-Clinical Programs
25 Pre-Clinical Programs
Slide 26: UIO Next Generation Oncolytic Virus
26 UIO 524 Next Generation Oncolytic Virus
Slide 27: Next Generation Oncolytic Virus: UIO-524
Next Generation Oncolytic Virus: UIO-524 27 High lytic capacity, immunogenicity, selective replication and manufacturing scale up UIO-524: engineered adenovirus type 5 based oncolytic virus • Hybrid promoter (SPARC-KR) to drive stromal-tumor specific virus replication • Armed with three powerful imm
Slide 28: UIO 524: Preclinical PoC & Initial Focus for Clinical Development
28 UIO 524: Preclinical PoC & Initial Focus for Clinical Development 7 14 21 28 400 800 1200 1600 0 0 Human A549 NSCLC (immuno-compromised mice) Tumor Volume ( mm3 ) Days PBS UIO-524 Significant oncolytic activity demonstrated with UIO-524 in experimental tumor model Low grade Muscle Invasive Bladde
Slide 29: TTX Drug Design Engine
29 TTX Drug Design Engine
Slide 30: TTX Tunable Drug Design Engine
TTX Tunable Drug Design Engine 30 Payload diversity Size Smart release linkers Enhanced targeting Nanometers Microns Non-cleavable pH sensitive Tissue-specific Time-sensitive Polymers Biomolecules (e.g. glucose) mAbs Peptides Tunable Platform Customizable to desired size, payload and pharmacokinetic
Slide 31: TTX-siPD-L1 RNAi-based Checkpoint Inhibitor
31 TTX-siPD-L1 RNAi-based Checkpoint Inhibitor
Slide 32: Traditional ICI vs TTX-siPD-L1: Mechanistic & Clinical Comparison
Traditional ICI* vs TTX-siPD-L1: Mechanistic & Clinical Comparison 32 Properties Traditional ICI* TTX-siPD-L1 Mechanism Blocks PD-1/PD-L1 interaction at the cell surface siRNA silences PD-L1 gene expression inside tumor cells Targeting Systemic immune activation; broad exposure Tumor-targeted delive
Slide 33: TTX-siPD-L1 Generated Robust Preclinical Response in Mice
TTX-siPD-L1 Generated Robust Preclinical Response in Mice 33 Results: • High-dose TTX-siPD-L1 + gemcitabine regressed pancreatic tumors by 90% within the first two weeks of treatment and delayed tumor growth. (Figure A above) • Treatment increased survival - 67% of the experimental animals survived
Slide 34: TTX-RIGA A PRR Agonist
34 TTX-RIGA A PRR Agonist
Slide 35: TTX-RIGA: RIG-I Signaling Properties
TTX-RIGA: RIG-I Signaling 35 Properties Traditional ICI* TTX-RIGA Mechanism Activate RIG-I broadly, often requiring high doses Tumor-targeted RIG-I activation via nanoparticle delivery and template-based activation Targeting Limited tumor selectivity; need for local injection Preferential activation
Slide 36: TTX-RIGA: In Vivo Efficacy
TTX-RIGA: In Vivo Efficacy 36 C57BL/6 mice were implanted s.c. with B16-F10 cells. Treatment was initiated once tumors were established. Treatment continued until day 6 after tumor implantation. On day 12 after the beginning of treatment, a secondary tumor challenge with the same cell line was perfo
Slide 37: TTX Pre-Clinical Programs: Moving Forward
TTX Pre-Clinical Programs: Moving Forward 37 • Developing nucleic acid-based therapeutics against cancer depends critically on successful delivery to tumors and metastases • TTX has shown successful delivery to cancerous lesions, including in humans • The efficacy of TTX-based nucleic acid therapeut
Slide 38: Corporate Finance Overview
38 Corporate Finance Overview
Slide 39: Recent Corporate Developments
Recent Corporate Developments 39 Q4 25 Q1 26 Q2 26 Acquisition of Polynoma Series A Pref. $25 million investment by CK Life Sciences Series B Pref. Licensing of immuno-oncolytic portfolio from Unleash Immuno Oncolytics Series C Pref. $20 million SEPA transaction with Yorkville Advisors Conv. Notes C
Slide 40: Capital Structure
Capital Structure 40 Share Price June 11, 2026 $5.69 Shares Outstanding (000) * June 11, 2026 950 Market Capitalization ($mm) June 11, 2026 $5.4 Shares Outstanding (000) * Pro Forma 18,655 Market Capitalization ($mm) Pro Forma $106.1 Long-Term Debt Mar 31, 2026 - - - Cash & Equivalents ($mm) Mar 31,
Slide 41: Investment Thesis
41 Investment Thesis
Slide 42: Investment Thesis
Investment Thesis 42 "We have built a three-platform oncology company with a pipeline that would cost multiples of our current market cap to replicate from scratch. That gap closes with execution." Philippe P. Calais, CEO Building an innovative and differentiated oncology company to meaningfully imp
Slide 43: Near Term Catalysts – Each a Potential Inflection Point
Near Term Catalysts – Each a Potential Inflection Point 43 Q2 26 Q3 26 Q4 26 1H 27 2H27 TTX-MC138 Phase 2a enrollment initiation TTX-MC138 Phase 2a enrollment update TTX-MC138 Phase 2a preliminary results TTX-MC138 Phase 1a results at major oncology conference Phase 2a enrollment completion TTX-MC13
Slide 44: TransCode Therapeutics
TRANS CODE DinERABPEUTICS™